Conversational AI organization Openstream.ai announced a new patent for automated digital twin technology that gives EVA, or enterprise virtual assistant, users the ability to utilize virtual assistants that are digital twins of human experts in their respective fields.
The digital twins share their human counterparts’ knowledge and unique personas and engage in empathetic, hallucination-free conversations with end-users.
The twins will be presented as AI-enabled avatars, virtual or voice agents, and will engage users in any language. Users can deploy twins for customer support, employee help desks and copilot use cases.
“The ability to build and deploy Digital Twins of Expert humans in the enterprise has been the holy grail of AI endeavors within the expert community for several decades. Our latest innovation is a major milestone towards achieving this goal,” Openstream.ai CEO Raj Tumuluri, said in a statement.
“Going beyond mere talking heads, they need to be effective communicators with the ability to observe, understand, and engage at many levels employing various nuances of human conversation through facial expressions, intonation and non-verbal cues.”
THE LARGER TREND
The global digital twin market size for 2023 was estimated at $16.75 billion, and it’s projected to grow 35.7% by 2030.
Openstream.ai was founded in 2008 and released its EVA virtual assistant platform in 2013.
Earlier this month, the New Jersey-based company announced a patent for cooperative, plan-based, utterance-guided multimodal dialogue. The technology allows virtual agents to understand user intentions through multimodal inputs to generate dialogue without a script.
California-based metabolic health-focused Twin Health announced in December it secured $50 million in funding, led by Temasek, with additional investment from Sofina, ICONIQ Growth, Peak XV and Helena. The company also garnered $140 million in Series C funding in 2021.
AI-enabled clinical trials company Unlearn raised $50 million in 2021, led by Insight Partners.
The company brought in an additional $50 million in February of this year, which the company will use to grow its data and invest in research and development and engineering capabilities.
Singaporean-based startup Mesh Bio, which offers digital twin chronic disease-management solutions, also raised $3.5 million in Series A funding in February. The funding round, led by East Ventures, aims for Mesh Bio to scale its solutions deployment across Hong Kong and Southeast Asia.
